Study to Assess the Long-term Safety of Dupilumab Administered in Participants ≥6 Months to <18 Years of Age With Atopic Dermatitis (AD) (NCT02612454)
An Open-Label Extension Study to Assess the Long-Term Safety and Efficacy of Dupilumab in Patients ≥6 Months to <18 Years of Age With Atopic Dermatitis
🩺 Plain-English Summary (8th-Grade Level)
The primary objective of the study is to assess the long-term safety of dupilumab in pediatric participants with AD. The secondary objectives of the study are: * To assess the long-term efficacy of dupilumab in pediatric participants with AD * To assess the trough concentrations of functional dupilumab in serum and the immunogenicity in pediatric participants with AD after re-treatment with dupilumab Optional Pre-filled Pen (PFP) Sub-Study in pediatric patients ≥2 to \<12 years of age with AD Co-Primary Objectives are: * To evaluate the pharmacokinetic (PK) of dupilumab PFPs * To evaluate the safety of dupilumab PFPs Secondary Objective is: \- To evaluate the immunogenicity of dupilumab PFPs
Who can join: Review the eligibility criteria below.
Location: Regeneron Investigational Site — Birmingham, Alabama
Age range: 6 Months to 17 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (84 Sites)
Showing the first 25 of 84 sites.
- Regeneron Investigational Site — Birmingham, Alabama
- Regeneron Investigational Site — Gilbert, Arizona
- Regeneron Investigational Site — Bakersfield, California
- Regeneron Investigational Site — Long Beach, California
- Regeneron Investigational Site — Los Angeles, California
- Regeneron Investigational site — Mission Viejo, California
- Regeneron Investigational Site — Orange, California
- Regeneron Investigational Site — Palo Alto, California
- Regeneron Investigational Site — Rolling Hills Estates, California
- Regeneron Investigational Site — San Diego, California
- Regeneron Investigational Site — Centennial, Colorado
- Regeneron Investigational Site — Washington D.C., District of Columbia
- Regeneron Investigational Site — Coral Gables, Florida
- Regeneron Investigational Site — Tampa, Florida
- Regeneron Investigational Site — Tampa, Florida
- Regeneron Investigational Site — Columbus, Georgia
- Regeneron Investigational Site — Macon, Georgia
- Regeneron Investigational Site — Sandy Springs, Georgia
- Regeneron Investigational Site — Chicago, Illinois
- Regeneron Investigational Site — Skokie, Illinois
- Regeneron Investigational site — Plainfield, Indiana
- Regeneron Investigational Site — Rockville, Maryland
- Regeneron Investigational Site — Boston, Massachusetts
- Regeneron Investigational Site — Boston, Massachusetts
- Regeneron Investigational Site — Ypsilanti, Michigan
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Atopic Dermatitis
- A Study to See How Well Lebrikizumab Works in Adults and Adolescents With Moderate Atopic Dermatitis (Eczema) and High Itch Burden — Birmingham, Alabama
- ATI-045 Versus Placebo in Patients With Moderate-to-Severe Atopic Dermatitis — Phoenix, Arizona
- A Study of Barzolvolimab in Patients With Atopic Dermatitis — Birmingham, Alabama
- Defining the Skin and Blood Biomarkers of Pediatric Atopic Dermatitis — Chicago, Illinois
- A Study of KT-621 Administered Orally to Participants With Moderate to Severe Atopic Dermatitis — Birmingham, Alabama
- A Study Evaluating APG777 in Atopic Dermatitis — Fountain Valley, California
Explore by condition: All Atopic Dermatitis clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Review the official NIH record below to find the coordinating site.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.